ChipCare's handheld cell analysis technology given impetus by $2.05 mln deal
ChipCare Corp., a Toronto-based developer of a handheld cell analyzer for medical testing, has secured $2.05 million in venture capital funding. Investors include Maple Leaf Angels, MaRS Innovation and the University of Toronto, as well as Grand Challenges Canada and the Canadian government. Investment proceeds will be used to further refine the functionality of ChipCare's device, develop a more robust and cost-effective prototype, and commercialize it over the next three years.
17 September 2013•3 mins read
